Ezetimibe
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Using the evidence pack fields directly (predicted_indications[0] = hyperlipoproteinemia, score 0.9963, evidence_level L1) as the basis for the report, following the fixed section order.
Ezetimibe: From Hypercholesterolaemia to Hyperlipoproteinemia
One-Sentence Summary
Ezetimibe is a cholesterol absorption inhibitor established for hypercholesterolaemia and mixed dyslipidaemia. The TxGNN model predicts it may also be effective for Hyperlipoproteinemia, a closely related lipid disorder, with 50 clinical trials and 19 publications currently available as supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not itemised in this evidence pack (no licence records supplied); ezetimibe is established as a cholesterol absorption inhibitor for hypercholesterolaemia/mixed dyslipidaemia |
| Predicted New Indication | Hyperlipoproteinemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is flagged as a data gap in this evidence pack (DG002, High severity). However, the repurposing rationale attached to this candidate provides pharmacological detail: ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) cholesterol transporter at the intestinal brush border, blocking absorption of both dietary and biliary cholesterol. This reduces hepatic cholesterol stores and upregulates LDL receptor expression, lowering circulating LDL-C.
Hyperlipoproteinemia is a broad classification of lipid disorders characterised by elevated LDL-C and/or triglycerides — the same physiological axis that ezetimibe’s NPC1L1-mediated mechanism directly targets. This is not a distant cross-indication extrapolation; it sits within the drug’s core pharmacological action, which is why the evidence base is unusually dense (50 registered trials, 19 publications) for a “predicted” indication.
This is reflected in the trial record itself: numerous completed Phase 3 studies test ezetimibe (alone or in fixed-dose combinations with simvastatin, fenofibrate, niacin, or newer agents such as obicetrapib) specifically in mixed hyperlipidaemia and related lipid disorders, alongside large-scale post-marketing surveillance programmes in Japan and the Philippines confirming real-world safety and efficacy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00093899 | Phase 3 | Completed | 611 | Ezetimibe/simvastatin plus fenofibrate coadministration for cholesterol lowering in mixed hyperlipidaemia — key drug-specific efficacy trial |
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE trial: ezetimibe + high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in heterozygous FH |
| NCT00271817 | Phase 3 | Completed | 1,220 | Ezetimibe/simvastatin + extended-release niacin vs monotherapy in Type IIa/IIb hyperlipidaemia |
| NCT06005597 | Phase 3 | Completed | 407 | Obicetrapib 10 mg + ezetimibe 10 mg fixed-dose combination on top of maximally tolerated lipid therapy in HeFH/ASCVD |
| NCT00092560 | Phase 3 | Completed | 587 | Fenofibrate + ezetimibe coadministration: efficacy and safety in mixed hyperlipidaemia |
| NCT00704444 | N/A (post-marketing) | Completed | 11,332 | Large Japanese post-marketing surveillance of Zetia (ezetimibe) mono/combination therapy — real-world safety and efficacy |
| NCT00704535 | N/A (post-marketing) | Completed | 4,105 | Filipino post-marketing surveillance of ezetimibe safety, tolerability and efficacy |
| NCT00705211 | N/A (post-marketing) | Completed | 1,794 | 52-week long-term Japanese post-marketing surveillance of Zetia mono/combination therapy |
| NCT00655265 | Phase 4 | Completed | 86 | Colesevelam as add-on to statin + ezetimibe in difficult-to-treat familial hypercholesterolaemia |
| NCT00189085 | Phase 4 | Completed | 20 | Effect of ezetimibe on postprandial hyperlipidaemia and endothelial dysfunction in metabolic syndrome |
Note: 50 trials in total are recorded against this indication in the evidence pack; the 10 above were prioritised by relevance grade, phase and enrolment size.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40347969 | 2025 | RCT | Lancet | TANDEM Phase 3 trial: obicetrapib + ezetimibe fixed-dose combination significantly lowers LDL-C |
| 41206969 | 2026 | RCT | JAMA | RCT of oral PCSK9 inhibitor enlicitide in HeFH patients not at LDL-C goal despite existing lipid-lowering therapy (including ezetimibe) |
| 25939291 | 2015 | Review | Cardiology Clinics | Overview of familial hypercholesterolaemia management, with ezetimibe as an LDL-C-lowering adjunct to statins |
| 38599725 | 2024 | Review | Indian Heart Journal | FH epidemiology, underdiagnosis/undertreatment and drug therapy overview |
| 34480646 | 2021 | Review | Current Cardiology Reports | Global burden and management approaches to familial hypercholesterolaemia |
| 29219151 | 2017 | Review | Nature Reviews Disease Primers | Comprehensive FH primer covering LDLR/APOB/PCSK9 pathways and treatment options |
| 37762244 | 2023 | Review | Int J Molecular Sciences | Pathophysiology, diagnosis and treatment of postprandial hyperlipidaemia |
| 40682836 | 2025 | Review | Molecular Medicine Reports | Review of current drugs targeting hyperlipidaemia |
| 35593194 | 2022 | Review | J Cardiovasc Pharmacol Ther | Comprehensive review of PCSK9 inhibitors, contextualising statin/ezetimibe intolerance |
| 23956253 | 2013 | Review | European Heart Journal | EAS consensus statement on underdiagnosis/undertreatment of FH, with screening and treatment guidance |
Note: 19 publications in total are recorded against this indication; the 10 above were prioritised by study type (RCT first) and recency.
UK Market Information
No marketing authorisation entries are recorded against ezetimibe in this evidence pack (0 licences on file; market status recorded as Not Marketed). Before any further evaluation proceeds, current UK licensing and product status (e.g. Ezetrol, or combination products) should be confirmed directly via the MHRA Products database and the current BNF entry.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: this evidence pack’s structured safety fields (key warnings, contraindications, drug interactions) were not populated at the time of this data cutoff, and label warnings/contraindications are flagged as a blocking data gap (DG001) preventing an initial safety assessment.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 RCTs (e.g. NCT00093899, the ENHANCE trial NCT00552097, NCT00271817, NCT06005597) directly evaluate ezetimibe-containing regimens in hyperlipidaemia and closely related lipid disorders, meeting the L1 evidence threshold. However, ezetimibe currently has no UK marketing authorisation on file in this evidence pack, and a blocking safety data gap (SmPC warnings/contraindications) means the candidate cannot yet clear an initial safety screen.
To proceed, the following is needed:
- SmPC/labelling warnings and contraindications (currently blocking — DG001)
- Confirmed mechanism-of-action data via DrugBank (DG002)
- Verification of current UK marketing authorisation status via the MHRA Products database
- A completed drug–drug interaction profile (DDI query currently returned no results)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.